NBIX Neurocrine Biosciences, Inc. Stock Quote

NBIX [NASD]

Index	-	P/E	116.05	EPS (ttm)	0.93	Insider Own	1.00%	Shs Outstand	93.30M	Perf Week	-3.91%
Market Cap	9.23B	Forward P/E	32.15	EPS next Y	3.35	Insider Trans	-30.80%	Shs Float	90.70M	Perf Month	12.98%
Income	93.40M	PEG	-	EPS next Q	0.57	Inst Own	99.40%	Short Float	4.75%	Perf Quarter	7.87%
Sales	1.04B	P/S	8.86	EPS this Y	74.70%	Inst Trans	1.56%	Short Ratio	4.56	Perf Half Y	-17.49%
Book/sh	8.62	P/B	12.49	EPS next Y	205.10%	ROA	6.60%	Target Price	123.76	Perf Year	1.28%
Cash/sh	11.02	P/C	9.77	EPS next 5Y	-	ROE	12.60%	52W Range	72.14 - 136.26	Perf YTD	12.35%
Dividend	-	P/FCF	39.62	EPS past 5Y	19.90%	ROI	6.00%	52W High	-20.97%	Beta	0.89
Dividend %	-	Quick Ratio	1.90	Sales past 5Y	-	Gross Margin	99.10%	52W Low	49.28%	ATR	4.00
Employees	700	Current Ratio	1.90	Sales Q/Q	16.40%	Oper. Margin	13.40%	RSI (14)	61.00	Volatility	4.09% 3.81%
Optionable	Yes	Debt/Eq	0.53	EPS Q/Q	-210.30%	Profit Margin	9.00%	Rel Volume	0.64	Prev Close	109.29
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 09 AMC	Payout	0.00%	Avg Volume	944.20K	Price	107.69
Recom	2.00	SMA20	6.57%	SMA50	11.26%	SMA200	0.21%	Volume	603,777	Change	-1.46%

Sep-30-20

Initiated

The Benchmark Company

Hold

Aug-04-20

Downgrade

JP Morgan

Overweight → Neutral

$136

Jun-29-20

Downgrade

Goldman

Buy → Neutral

$135

Jun-09-20

Initiated

Wedbush

Outperform

$147

Mar-06-20

Initiated

Citigroup

Buy

$124

Feb-27-20

Initiated

Barclays

Equal Weight

$105

Feb-24-20

Initiated

William Blair

Outperform

Feb-06-20

Initiated

Mizuho

Neutral

Feb-05-20

Reiterated

H.C. Wainwright

Buy

$102 → $125

Dec-13-19

Downgrade

Credit Suisse

Outperform → Neutral

$110

Aug-07-19

Initiated

RBC Capital Mkts

Outperform

$118

Jul-16-19

Initiated

Oppenheimer

Outperform

$100

Jun-05-19

Initiated

Guggenheim

Neutral

May-21-19

Initiated

Credit Suisse

Outperform

$95

Apr-22-19

Upgrade

JP Morgan

Neutral → Overweight

Apr-12-19

Initiated

Evercore ISI

Outperform

Feb-06-19

Reiterated

BofA/Merrill

Buy

$124 → $117

Jan-23-19

Downgrade

JP Morgan

Overweight → Neutral

Dec-13-18

Initiated

Goldman

Buy

$103

Nov-21-18

Initiated

Canaccord Genuity

Buy

$111

Jan-08-21 10:15AM	Neurocrine Biosciences Shares Rise Despite Disappointing Q4 Earnings; Target Price $121 FX Empire +9.00%
07:30AM	Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones PR Newswire
Jan-04-21 04:01PM	Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-22-20 04:17PM	Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program GlobeNewswire
Dec-21-20 11:36AM	Is NBIX A Good Stock To Buy Now? Insider Monkey
04:22AM	Should You Be Adding Neurocrine Biosciences (NASDAQ:NBIX) To Your Watchlist Today? Simply Wall St.
Dec-11-20 08:58AM	Is Neurocrine Biosciences (NBIX) a Smart Long-term Buy? Insider Monkey
Dec-09-20 07:51AM	New Strong Sell Stocks for December 9th Zacks
Nov-19-20 09:00AM	Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
08:00AM	Neurocrine Biosciences Announces Repurchase of Convertible Notes PR Newswire
Nov-13-20 07:29AM	Results: Neurocrine Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts Simply Wall St.
Nov-10-20 04:00PM	Neurocrine Biosciences Inc (NBIX) Q3 2020 Earnings Call Transcript Motley Fool -14.81%
Nov-09-20 05:15PM	Neurocrine Biosciences (NBIX) Reports Q3 Loss, Lags Revenue Estimates Zacks +6.72%
04:54PM	Recap: Neurocrine Biosciences Q3 Earnings Benzinga
04:01PM	Neurocrine Biosciences Reports Third Quarter 2020 Financial Results PR Newswire
02:45PM	Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
09:00AM	Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Nov-06-20 10:18AM	Preview: Neurocrine Biosciences's Earnings Benzinga
Nov-04-20 11:10AM	Was The Smart Money Wrong About Neurocrine Biosciences, Inc. (NBIX)? Insider Monkey +13.00%
Nov-02-20 12:31PM	Earnings Preview: Neurocrine Biosciences (NBIX) Q3 Earnings Expected to Decline Zacks
11:45AM	Neurocrine (NBIX) to Report Q3 Earnings: What's in Store? Zacks
Oct-19-20 07:56AM	New Strong Sell Stocks for October 19th Zacks
Oct-15-20 10:45AM	Is Neurocrine Biosciences (NASDAQ:NBIX) Using Too Much Debt? Simply Wall St.
Oct-08-20 08:00AM	Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy GlobeNewswire
Oct-07-20 06:45AM	Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments, an Online Community Platform and Charitable Initiative to Support, Inspire and Connect People During the Pandemic PR Newswire
Oct-06-20 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results PR Newswire
Sep-30-20 09:35AM	Benzinga's Top Upgrades, Downgrades For September 30, 2020 Benzinga
Sep-28-20 04:01PM	Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting PR Newswire
Sep-14-20 01:24PM	Neurocrine Biosciences Officially Begins Marketing Its New Parkinson's Disease Drug Motley Fool +5.62%
08:43AM	Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes PR Newswire
08:30AM	Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease Reuters
Sep-11-20 03:27PM	Parkinson's Disease Patients Get Long-Term Benefits From Experimental Gene Therapy Motley Fool
11:36AM	Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinsons Disease GlobeNewswire
11:34AM	Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020 PR Newswire
11:32AM	Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease PR Newswire
Sep-09-20 09:48PM	Neurocrine Biosciences (NBIX): Hedge Funds In Wait-and-See Mode Insider Monkey
03:12PM	Neurocrine Biosciences (NASDAQ:NBIX) Shareholders Have Enjoyed An Impressive 102% Share Price Gain Simply Wall St.
Sep-08-20 04:01PM	Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference PR Newswire
Sep-03-20 04:06PM	Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings PR Newswire
Sep-02-20 04:01PM	Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference PR Newswire
Aug-28-20 10:11AM	Looking Into Neurocrine Biosciences's Return On Capital Employed Benzinga
Aug-04-20 09:30AM	Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript Motley Fool
08:38AM	How Is Neurocrine Biosciences' (NASDAQ:NBIX) CEO Paid Relative To Peers? Simply Wall St.
06:34AM	How Neurocrine Biosciences Crushed It in Q2 Motley Fool
Aug-03-20 05:15PM	Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates Zacks
04:37PM	Neurocrine Biosciences Stock Pops After Earnings Double, Shatter Views Investor's Business Daily
04:01PM	Neurocrine Biosciences Reports Second Quarter 2020 Financial Results PR Newswire
Jul-30-20 04:01PM	Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020 PR Newswire
Jul-27-20 12:31PM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Jul-13-20 07:16PM	Did Hedge Funds Make The Right Call On Neurocrine Biosciences, Inc. (NBIX)? Insider Monkey
04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results PR Newswire
Jul-01-20 07:00AM	FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs Reuters
Jun-25-20 12:17PM	The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY Zacks
Jun-17-20 04:04PM	Neurocrine Adds to Pipeline With $2 Billion Takeda Deal GuruFocus.com
Jun-16-20 07:00AM	Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders Business Wire
Jun-15-20 04:01PM	Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference PR Newswire
Jun-08-20 11:01AM	/C O R R E C T I O N -- Neurocrine Biosciences, Inc./ PR Newswire
Jun-05-20 11:26AM	Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run Investor's Business Daily
Jun-04-20 04:01PM	Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast PR Newswire
Jun-03-20 01:44AM	Edited Transcript of NBIX earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-01-20 11:46AM	AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding Zacks
May-29-20 04:13PM	FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women PR Newswire
May-26-20 04:01PM	Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference PR Newswire
09:39AM	Are Investors Undervaluing Neurocrine Biosciences, Inc. (NASDAQ:NBIX) By 33%? Simply Wall St.
May-23-20 08:00AM	Teladoc, Neurocrine Bio Lead Five Healthy Stocks To Monitor Closely Investor's Business Daily
May-18-20 12:16PM	Neurocrine Biosciences Soars Into Buy Zone Investor's Business Daily Video +6.79%
May-14-20 07:29PM	Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference PR Newswire
06:27AM	Is Now a Good Time To Buy Neurocrine Biosciences? Motley Fool
May-13-20 04:01PM	Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform PR Newswire
02:58PM	The Top 10 Stocks of the Past Decade Kiplinger
02:38PM	IBD 50 Stocks To Watch: Top Biotech Scores Price-Target Hikes As It Nears Buy Point Investor's Business Daily
May-12-20 04:55PM	This IBD Stock Of The Day Is Setting Up After A Bullish First-Quarter Report Investor's Business Daily
May-11-20 04:01PM	Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy PR Newswire
May-07-20 08:09PM	Neurocrine Biosciences Q1 Beats on Earnings, Revenue Motley Fool +5.28%
05:30PM	Neurocrine Biosciences Inc (NBIX) Q1 2020 Earnings Call Transcript Motley Fool
04:01PM	Neurocrine Biosciences Announces New Data Published from the Largest Real-World Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disorders PR Newswire
May-06-20 05:35PM	Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Top Estimates Zacks
04:01PM	Neurocrine Biosciences Reports First Quarter 2020 Financial Results PR Newswire
May-05-20 04:01PM	Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020 PR Newswire
08:35AM	Is a Surprise Coming for Neurocrine Biosciences (NBIX) This Earnings Season? Zacks
Apr-29-20 12:34PM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? Zacks
Apr-27-20 11:07AM	Neurocrine Biosciences Parkinson's Drug Cleared by FDA TheStreet.com
10:24AM	Neurocrine's stock is up on FDA approval of Parkinson's drug MarketWatch
07:39AM	U.S. FDA approves Neurocrine's Parkinson's therapy Reuters
07:30AM	Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes PR Newswire
Apr-24-20 11:41AM	7 Beautiful Biotech Stocks to Buy Here InvestorPlace
Apr-20-20 01:31PM	Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet? Simply Wall St.
Apr-15-20 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results PR Newswire
Apr-03-20 08:30AM	Neurocrine Biosciences Provides COVID-19 Business Update PR Newswire
Mar-30-20 06:06PM	FDA Decisions on 5 Drugs Expected in 2nd Quarter GuruFocus.com
Mar-27-20 12:45PM	A Trio of Stocks Growing Capex Fast GuruFocus.com
Mar-26-20 11:40AM	COLL or NBIX: Which Is the Better Value Stock Right Now? Zacks
Mar-18-20 02:29PM	Top Biotech Stocks for Q2 2020 Investopedia -5.65%
Mar-14-20 10:59AM	Should Neurocrine Biosciences (NASDAQ:NBIX) Be Disappointed With Their 97% Profit? Simply Wall St.
Mar-11-20 08:53PM	Hedge Funds Arent Crazy About Neurocrine Biosciences, Inc. (NBIX) Anymore Insider Monkey -6.87%
02:45PM	Stock Upgrades: Neurocrine Biosciences Shows Rising Relative Strength Investor's Business Daily
Mar-10-20 11:40AM	COLL or NBIX: Which Is the Better Value Stock Right Now? Zacks
Mar-05-20 02:38PM	Neurocrine Biosciences Stock Rating Jumps Amid Expanded Use Plans Investor's Business Daily
Feb-25-20 04:01PM	Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference PR Newswire
Feb-19-20 12:08PM	Neurocrine Biosciences Earns Membership In 95-Plus Composite Rating Club Investor's Business Daily

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL A Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GORMAN KEVIN CHARLES	Chief Executive Officer	Jan 08	Option Exercise	8.65	308,250	2,667,797	605,872	Jan 12 04:16 PM
ROBERTS EIRY	Chief Medical Officer	Jan 08	Sale	111.06	2,632	292,297	15,845	Jan 12 04:17 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Jan 08	Sale	110.22	308,250	33,973,877	441,071	Jan 12 04:16 PM
ABERNETHY MATT	Chief Financial Officer	Dec 01	Sale	94.66	1,645	155,721	11,494	Dec 02 04:12 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 12	Sale	90.71	2,257	204,723	17,405	Nov 16 06:27 PM
ROBERTS EIRY	Chief Medical Officer	Nov 12	Sale	90.74	2,257	204,810	13,477	Nov 16 06:23 PM
Lloyd-Smith Malcolm	Chief Regulatory Officer	Nov 12	Sale	90.73	2,257	204,776	29,002	Nov 16 06:21 PM
Lippoldt Darin	Chief Legal Officer	Nov 12	Sale	90.72	2,257	204,755	30,082	Nov 16 06:20 PM
Grigoriadis Dimitri E.	Chief Research Officer	Nov 12	Sale	90.73	2,257	204,784	81,624	Nov 16 06:19 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Nov 12	Sale	90.78	3,390	307,748	441,071	Nov 16 06:16 PM
Gano Kyle	Chief Business Development Off	Nov 12	Sale	90.73	2,257	204,770	98,028	Nov 16 06:11 PM
Cooke Julie	Chief Human Resources Officer	Nov 12	Sale	90.73	2,257	204,778	11,580	Nov 16 06:10 PM
Bozigian Haig P.	Chief Development Officer	Nov 12	Sale	90.74	2,257	204,806	152,694	Nov 16 06:08 PM
ABERNETHY MATT	Chief Financial Officer	Nov 12	Sale	90.74	2,257	204,810	10,014	Nov 16 06:02 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 02	Option Exercise	35.99	20,595	741,214	35,969	Nov 04 06:09 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 02	Sale	96.53	20,595	1,987,972	15,374	Nov 04 06:09 PM
Cooke Julie	Chief Human Resources Officer	Oct 02	Sale	95.26	987	94,022	9,549	Oct 06 04:05 PM
ROBERTS EIRY	Chief Medical Officer	Aug 05	Sale	118.84	2,257	268,225	11,446	Aug 07 07:51 PM
Lloyd-Smith Malcolm	Chief Regulatory Officer	Aug 05	Sale	118.86	2,257	268,277	26,971	Aug 07 07:47 PM
Lippoldt Darin	Chief Legal Officer	Aug 05	Sale	118.87	2,257	268,297	28,051	Aug 07 07:40 PM
Grigoriadis Dimitri E.	Chief Research Officer	Aug 05	Sale	118.83	2,257	268,200	79,593	Aug 07 07:36 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Aug 05	Sale	118.91	3,390	403,101	438,021	Aug 07 07:29 PM
Gano Kyle	Chief Business Development Off	Aug 05	Sale	118.87	2,257	268,286	95,997	Aug 07 07:24 PM
Cooke Julie	Chief Human Resources Officer	Aug 05	Sale	118.91	2,257	268,383	8,661	Aug 07 07:21 PM
Bozigian Haig P.	Chief Development Officer	Aug 05	Sale	118.89	2,257	268,324	150,663	Aug 07 07:14 PM
BENEVICH ERIC	Chief Commercial Officer	Aug 05	Sale	118.85	2,257	268,254	15,374	Aug 07 06:35 PM
ABERNETHY MATT	Chief Financial Officer	Aug 05	Sale	118.90	2,257	268,356	7,983	Aug 07 06:22 PM
Lippoldt Darin	Chief Legal Officer	Jul 09	Option Exercise	35.99	1,657	59,635	27,678	Jul 10 04:26 PM
Lippoldt Darin	Chief Legal Officer	Jul 09	Sale	136.02	1,657	225,386	26,021	Jul 10 04:26 PM
Lippoldt Darin	Chief Legal Officer	Jun 23	Option Exercise	32.99	5,000	164,950	31,021	Jun 25 04:15 PM
ROBERTS EIRY	Chief Medical Officer	Jun 23	Option Exercise	77.81	5,000	389,050	14,416	Jun 25 04:19 PM
Lippoldt Darin	Chief Legal Officer	Jun 23	Sale	130.00	5,000	650,000	26,021	Jun 25 04:15 PM
ROBERTS EIRY	Chief Medical Officer	Jun 23	Sale	130.00	5,000	650,000	9,416	Jun 25 04:19 PM
Grigoriadis Dimitri E.	Chief Research Officer	Jun 11	Option Exercise	35.90	5,571	199,976	77,563	Jun 15 05:31 PM
Grigoriadis Dimitri E.	Chief Research Officer	May 19	Option Exercise	35.99	10,000	359,900	114,741	May 20 06:59 PM
Grigoriadis Dimitri E.	Chief Research Officer	May 19	Sale	126.55	42,749	5,409,933	71,992	May 20 06:59 PM
Lippoldt Darin	Chief Legal Officer	May 18	Option Exercise	32.99	5,000	164,950	31,021	May 20 07:15 PM
Grigoriadis Dimitri E.	Chief Research Officer	May 18	Option Exercise	35.99	10,000	359,900	114,741	May 20 06:59 PM
Grigoriadis Dimitri E.	Chief Research Officer	May 18	Sale	119.98	10,000	1,199,800	104,741	May 20 06:59 PM
Lippoldt Darin	Chief Legal Officer	May 18	Sale	120.00	5,000	600,000	26,021	May 20 07:15 PM
Bozigian Haig P.	Chief Development Officer	May 12	Option Exercise	63.10	61,555	3,884,054	167,204	May 14 08:09 PM
Bozigian Haig P.	Chief Development Officer	May 12	Sale	114.94	61,555	7,075,396	148,633	May 14 08:09 PM
ABERNETHY MATT	Chief Financial Officer	May 07	Option Exercise	73.60	15,000	1,104,000	20,953	May 11 08:17 PM
ABERNETHY MATT	Chief Financial Officer	May 07	Sale	110.21	15,000	1,653,134	5,953	May 11 08:17 PM
Grigoriadis Dimitri E.	Chief Research Officer	May 07	Sale	105.44	8,682	915,454	104,741	May 11 08:06 PM
SHERWIN STEPHEN A	Director	Apr 28	Sale	99.39	17,687	1,757,966	29,861	Apr 30 04:27 PM
ABERNETHY MATT	Chief Financial Officer	Apr 28	Sale	102.49	1,741	178,435	5,953	Apr 30 04:25 PM
ABERNETHY MATT	Chief Financial Officer	Apr 24	Sale	99.52	1,934	192,467	7,694	Apr 28 08:32 PM
ROBERTS EIRY	Chief Medical Officer	Apr 24	Sale	99.47	1,934	192,376	9,416	Apr 28 08:46 PM
Lloyd-Smith Malcolm	Chief Regulatory Officer	Apr 24	Sale	99.45	1,934	192,329	24,941	Apr 28 08:44 PM
Lippoldt Darin	Chief Legal Officer	Apr 24	Sale	99.49	1,934	192,416	26,021	Apr 28 08:43 PM
Grigoriadis Dimitri E.	Chief Research Officer	Apr 24	Sale	99.41	1,934	192,258	113,423	Apr 28 08:42 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Apr 24	Sale	99.45	2,906	289,016	434,971	Apr 28 08:41 PM
Gano Kyle	Chief Business Development Off	Apr 24	Sale	99.47	1,934	192,377	93,967	Apr 28 08:40 PM
Cooke Julie	Chief Human Resources Officer	Apr 24	Sale	99.46	1,934	192,364	6,631	Apr 28 08:38 PM
Bozigian Haig P.	Chief Development Officer	Apr 24	Sale	99.46	1,934	192,351	148,633	Apr 28 08:35 PM
BENEVICH ERIC	Chief Commercial Officer	Apr 24	Sale	99.45	1,934	192,338	13,344	Apr 28 08:33 PM
BENEVICH ERIC	Chief Commercial Officer	Apr 15	Sale	94.65	8,632	817,018	11,603	Apr 17 09:48 PM
Lloyd-Smith Malcolm	Chief Regulatory Officer	Feb 10	Option Exercise	59.66	28,969	1,728,147	39,127	Feb 11 07:21 PM
Lloyd-Smith Malcolm	Chief Regulatory Officer	Feb 10	Sale	104.56	28,969	3,029,086	23,200	Feb 11 07:21 PM
ROBERTS EIRY	Chief Medical Officer	Feb 07	Sale	103.31	1,623	167,675	7,452	Feb 11 07:23 PM
Lloyd-Smith Malcolm	Chief Regulatory Officer	Feb 07	Sale	103.28	1,015	104,827	23,200	Feb 11 07:21 PM
Lippoldt Darin	Chief Legal Officer	Feb 07	Sale	103.32	1,522	157,247	24,124	Feb 11 07:17 PM
Grigoriadis Dimitri E.	Chief Research Officer	Feb 07	Sale	103.31	1,218	125,833	111,682	Feb 11 07:16 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 07	Sale	103.35	3,248	335,696	432,357	Feb 11 07:14 PM
Gano Kyle	Chief Business Development Off	Feb 07	Sale	103.33	1,623	167,710	91,975	Feb 11 07:13 PM
Cooke Julie	Chief Human Resources Officer	Feb 07	Sale	103.26	913	94,276	4,643	Feb 11 07:10 PM
Bozigian Haig P.	Chief Development Officer	Feb 07	Sale	103.33	1,623	167,702	146,641	Feb 11 07:09 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 07	Sale	103.32	2,030	209,747	20,087	Feb 11 07:08 PM
ABERNETHY MATT	Chief Financial Officer	Feb 07	Sale	103.35	2,030	209,807	5,701	Feb 11 07:06 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 06	Sale	101.48	1,395	141,561	18,262	Feb 07 06:35 PM
Bozigian Haig P.	Chief Development Officer	Feb 06	Sale	101.56	1,395	141,670	145,180	Feb 07 06:37 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 06	Sale	101.56	4,343	441,068	429,436	Feb 07 06:44 PM
Lippoldt Darin	Chief Legal Officer	Feb 06	Sale	101.47	1,198	121,556	22,755	Feb 07 06:46 PM
Lloyd-Smith Malcolm	Chief Regulatory Officer	Feb 06	Sale	101.52	1,490	151,258	22,287	Feb 07 06:47 PM
Grigoriadis Dimitri E.	Chief Research Officer	Feb 06	Sale	101.44	803	81,456	110,587	Feb 07 06:50 PM
Gano Kyle	Chief Business Development Off	Feb 06	Sale	101.41	1,000	101,413	90,514	Feb 07 06:54 PM
Gano Kyle	Chief Business Development Off	Feb 05	Sale	103.05	3,690	380,262	87,204	Feb 07 06:54 PM
Grigoriadis Dimitri E.	Chief Research Officer	Feb 05	Sale	103.15	1,618	166,894	109,320	Feb 07 06:50 PM
Lloyd-Smith Malcolm	Chief Regulatory Officer	Feb 05	Sale	103.05	1,948	200,733	20,455	Feb 07 06:47 PM
Lippoldt Darin	Chief Legal Officer	Feb 05	Sale	102.98	1,750	180,207	21,133	Feb 07 06:46 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 05	Sale	103.09	5,449	561,726	423,351	Feb 07 06:44 PM
Cooke Julie	Chief Human Resources Officer	Feb 05	Sale	103.17	605	62,417	3,821	Feb 07 06:38 PM
Bozigian Haig P.	Chief Development Officer	Feb 05	Sale	103.02	2,046	210,779	143,292	Feb 07 06:37 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 05	Sale	103.03	1,954	201,311	16,279	Feb 07 06:35 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience